Patients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
Cytokine release syndrome (CRS), all grades, is observed in approximately 55%-80% of the patients with relapsed or refractory multiple myeloma and 45%-65% of the patients with B-cell non-Hodgkin ...
Chimeric antigen receptor T (CAR-T) cell therapy has significantly transformed the management of cancer, specifically in patients suffering from leukemia and lymphoma. This treatment approach entails ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners (MOLN) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage ...
Tumor immunotherapies, especially those leveraging T cells to identify and eliminate cancer cells, represent a major breakthrough in cancer treatment. However, many tumor-associated antigens are too ...
Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results